Breast cancer treatment: Drug Kisqali approval expanded for ... - NBC News
WEB2 days ago · The drug was found to reduce the risk of a patient's breast cancer coming back by 25%. The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to ...
New study finds triple-negative breast cancer tumors with an …
WEBApr 25, 2024 · A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
Pembrolizumab Boosts OS for Triple-Negative Breast Cancer
WEB2 days ago · Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab showed significant improvements in overall survival compared with placebo plus chemotherapy in patients with high-risk, early-stage triple-negative breast cancer. The findings, derived from the KEYSTONE-522 trial, strongly support using this pembrolizumab regimen as the standard-of-care therapy for this difficult-to ...
Breast Cancer News - ScienceDaily
WEB4 days ago · Breast cancer research including information on breast cancer symptoms, prevention strategies, screening techniques, and new breast cancer treatments.
Estrogen a more powerful breast cancer culprit than we realized
WEBMay 17, 2023 · A Harvard Medical School study shows the sex hormone estrogen — thus far thought to be only a fuel for breast cancer growth — can directly cause tumor-driving genomic rearrangements.
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
WEBJun 7, 2022 · The clinical trial, sponsored by the pharmaceutical companies Daiichi Sankyo and AstraZeneca and led by Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center, involved 557 patients with...
Experimental immunotherapy targets metastatic breast cancer
WEBFeb 1, 2022 · Many people with metastatic breast cancer can mount an immune reaction against their tumors, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumor-infiltrating lymphocytes (TILs).
Pembrolizumab for Advanced Triple-Negative Breast Cancer
WEBAug 9, 2022 · In the KEYNOTE-355 trial, 847 patients with advanced (unresectable, locally advanced, or metastatic) triple-negative breast cancer were randomly assigned to receive chemotherapy plus placebo or chemotherapy plus pembrolizumab.
Targeting HER2-positive breast cancer: advances and future …
WEBNov 7, 2022 · The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading...
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
- Some results have been removed